New help for tailoring treatments
Mayo Clinic researchers have discovered a key molecule that lets doctors identify one of the most aggressive types of kidney cancer. Patients with renal cell carcinoma who have higher levels of a molecule known as B7-H1 in their tumors are nearly five times more likely to die from the disease than patients with low levels or an absence of the molecule.
This key finding can help to improve treatment of the disease, or to serve as a target for new therapies. The findings are published in today’s online issue of the Proceedings of the National Academy of Sciences, http://www.pnas.org.
"Many people have hypothesized that if a cancer makes B7-H1, that cancer may be more aggressive because B7-H1 knocks down the host’s immune system, thereby permitting the tumor to grow without interference from the immune system," explains Eugene Kwon, M.D., the immunologist and urologist who led the study. "But there has been no evidence at the clinical level to demonstrate tumors that express B7-H1 are aggressive, so there’s been no way to prove this hypothesis."
Dr. Kwon’s group studied 196 samples from kidney tumors of patients treated at Mayo Clinic. They found that when patients express this molecule on their kidney cancer cells, they are at markedly increased risk both of the cancer spreading, and of dying from the cancer. "We found that when you have high levels of this molecule, your risk of dying from this cancer goes up almost five-fold," Dr. Kwon says.
Implications of Research
This molecule seems suited to be used as a biomarker by physicians to determine prognosis, according to the Mayo researchers. High levels of the molecule would indicate a poor prognosis, while low levels or its absence would suggest a good prognosis. The level of this molecule could also be used to help select the most effective treatments. For example, it’s possible that patients with high levels of B7-H1 may be the best candidates for immunotherapeutic treatment using agents such as Interleukin-2 (IL-2) and alpha interferon.
Furthermore, say the researchers, a drug developed to block B7-H1 could theoretically be created to improve the effectiveness of immunotherapy. For instance, an antibody could be developed that would bind B7-H1 and block its function. By doing so, either alone or in combination with standard therapy, this would potentially improve treatment responses of patients with kidney cancers by protecting their immune system from being shut down.
About Kidney Cancer
There are different kinds of kidney cancers. Renal cell carcinoma accounts for approximately 85 percent of all kidney cancers. In the United States, an estimated 35,000 patients will be diagnosed with kidney cancer and approximately 12,000 will die from this disease every year. It is the eighth most common cancer in men and the 10th most common cancer in women. In the United States, it is the sixth leading cause of cancer death.
The primary treatment for advanced kidney cancer -- Interleukin 2 -- has significant limitations. It is relatively toxic, can further sicken the patient and only elicits a response in 15-20 percent of all patients treated. This means 80-85 percent of patients are not significantly helped by it, but nonetheless exposed to its toxicity.
"That’s why we’re so interested in this molecule," says Dr. Kwon. "We think that by recognizing that B7-H1 may be an immune-suppressive molecule, we might be able to make patients much more receptive or responsive to immunotherapy using either IL-2 or some of the other agents that are out there just by manipulating B7-H1 appropriately. We could improve treatment outcomes, hopefully, and that’s what’s drastically needed for this disease."
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
Pain: Perception and motor impulses arise in the brain independently of one another
12.12.2018 | Technische Universität München
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
13.12.2018 | Life Sciences
13.12.2018 | Physics and Astronomy
13.12.2018 | Earth Sciences